Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallant Therapeutics allogeneic MSC therapy for canine atopic dermatitis
- Development stage
- Unknown
- Lead developer
- Gallant Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Gallant Therapeutics is developing an investigational allogeneic mesenchymal stem cell (MSC) therapy for canine atopic dermatitis (CAD), a chronic allergic skin condition affecting a significant portion of the canine population. The therapy utilizes uterine-derived mesenchymal stromal cells (UMSCs) administered intravenously to modulate immune responses and reduce skin inflammation. By targeting the underlying immune dysregulation rather than just managing symptoms, the therapy is designed to provide a longer duration of action compared to current daily or monthly treatments. It is currently in Phase 2 development (Controlled Field Study) and is being evaluated under the FDA Center for Veterinary Medicine's Veterinary Innovation Program.
- Other names
- allogeneic canine UMSCsuterine-derived mesenchymal stromal cellsCanine atopic dermatitis allogeneic MSC therapy
Beyond the preview
Go deeper on Gallant Therapeutics allogeneic MSC therapy for canine atopic dermatitis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gallant Therapeutics allogeneic MSC therapy for canine atopic dermatitis.